Latest China Nuokang Bio-Pharmaceutical Inc. (NKBP
Post# of 1
Posted On: 03/13/2014 11:39:12 AM
Latest China Nuokang Bio-Pharmaceutical Inc. (NKBP) Headlines
Entrec Corporation Approves 2014 Capital Expenditure Program and Appoints John M. Stevens President & CEO
Marketwire Canada - Wed Jan 15, 5:59AM CST
ENTREC Corporation ("ENTREC" or the "Company") (TSX VENTURE:ENT), a leading provider of heavy lift and heavy haul services, today approved a $46 million capital expenditure program for 2014. The program consists of growth capital expenditures of $34 million and $12 million in maintenance capital expenditures. ENTREC is also pleased to announce the appointment of Mr. John M. Stevens as its President and CEO. Mr. Stevens previously served as President and COO and will now replace Rod Marlin as CEO who has transitioned to the role of Executive Chairman.
7 Star Entertainment Inc. Announces 1-for-150 Reverse Stock Split and Corporate Name Change to 'SpectralCast Inc.'
Marketwire - Tue Jan 14, 3:15PM CST
7 STAR ENTERTAINNMENT, INC. (OTC Pink: SAEE) today announced that a 1-for-150 reverse stock split will be effective, and reflected in the price of its common stock, when trading opens on January 15th, 2014. The Company is simultaneously changing its name to SpectralCast, Inc.
China Nuokang Bio-Pharmaceutical Inc. Announces Completion of Merger
GlobeNewswire - Thu Feb 07, 3:55AM CST
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced the completion of the merger (the "Merger") with Kingbird Mergerco. Inc. ("Merger Sub"), a wholly-owned subsidiary of Kingbird Investment Inc. ("Parent"), an affiliate of Mr. Baizhong Xue, the Chairman and Chief Executive Officer of the Company, pursuant to the agreement and plan of merger (the "Merger Agreement") dated September 27, 2012, among the Company, Parent and Merger Sub, and, solely for the purposes of Section 6.16 thereof, Anglo China Bio-technology Investment Holdings Limited and Britain Ukan Technology Investment Holdings (Group) Limited. As a result of the merger, the Company became a direct wholly-owned subsidiary of Parent.
China Nuokang Bio-Pharmaceutical Inc. to Reconvene Adjourned Extraordinary General Meeting of Shareholders
GlobeNewswire - Tue Jan 29, 8:00AM CST
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company") announced today that it will reconvene the extraordinary general meeting of shareholders (the "EGM") that was previously adjourned on January 15, 2013. The EGM will be reconvened at 9:30 a.m. (Beijing time) on February 6, 2013, at 26th Floor, Gloucester Tower, The Landmark, 15 Queen's Road Central, Hong Kong, to consider and vote on, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger (the "Merger Agreement") dated September 27, 2012, among the Company, Kingbird Investment Inc. ("Parent") and Kingbird Mergerco. Inc. ("Merger Sub"), and, solely for the purposes of Section 6.16 thereof, Anglo China Bio-technology Investment Holdings Limited and Britain Ukan Technology Investment Holdings (Group) Limited, and the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands, substantially in the form attached as Exhibit A to the Merger Agreemen
Entrec Corporation Approves 2014 Capital Expenditure Program and Appoints John M. Stevens President & CEO
Marketwire Canada - Wed Jan 15, 5:59AM CST
ENTREC Corporation ("ENTREC" or the "Company") (TSX VENTURE:ENT), a leading provider of heavy lift and heavy haul services, today approved a $46 million capital expenditure program for 2014. The program consists of growth capital expenditures of $34 million and $12 million in maintenance capital expenditures. ENTREC is also pleased to announce the appointment of Mr. John M. Stevens as its President and CEO. Mr. Stevens previously served as President and COO and will now replace Rod Marlin as CEO who has transitioned to the role of Executive Chairman.
7 Star Entertainment Inc. Announces 1-for-150 Reverse Stock Split and Corporate Name Change to 'SpectralCast Inc.'
Marketwire - Tue Jan 14, 3:15PM CST
7 STAR ENTERTAINNMENT, INC. (OTC Pink: SAEE) today announced that a 1-for-150 reverse stock split will be effective, and reflected in the price of its common stock, when trading opens on January 15th, 2014. The Company is simultaneously changing its name to SpectralCast, Inc.
China Nuokang Bio-Pharmaceutical Inc. Announces Completion of Merger
GlobeNewswire - Thu Feb 07, 3:55AM CST
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced the completion of the merger (the "Merger") with Kingbird Mergerco. Inc. ("Merger Sub"), a wholly-owned subsidiary of Kingbird Investment Inc. ("Parent"), an affiliate of Mr. Baizhong Xue, the Chairman and Chief Executive Officer of the Company, pursuant to the agreement and plan of merger (the "Merger Agreement") dated September 27, 2012, among the Company, Parent and Merger Sub, and, solely for the purposes of Section 6.16 thereof, Anglo China Bio-technology Investment Holdings Limited and Britain Ukan Technology Investment Holdings (Group) Limited. As a result of the merger, the Company became a direct wholly-owned subsidiary of Parent.
China Nuokang Bio-Pharmaceutical Inc. to Reconvene Adjourned Extraordinary General Meeting of Shareholders
GlobeNewswire - Tue Jan 29, 8:00AM CST
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company") announced today that it will reconvene the extraordinary general meeting of shareholders (the "EGM") that was previously adjourned on January 15, 2013. The EGM will be reconvened at 9:30 a.m. (Beijing time) on February 6, 2013, at 26th Floor, Gloucester Tower, The Landmark, 15 Queen's Road Central, Hong Kong, to consider and vote on, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger (the "Merger Agreement") dated September 27, 2012, among the Company, Kingbird Investment Inc. ("Parent") and Kingbird Mergerco. Inc. ("Merger Sub"), and, solely for the purposes of Section 6.16 thereof, Anglo China Bio-technology Investment Holdings Limited and Britain Ukan Technology Investment Holdings (Group) Limited, and the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands, substantially in the form attached as Exhibit A to the Merger Agreemen
(0)
(0)China Nuokang Bio-Pharmaceutical Inc. (NKBP) Stock Research Links
Scroll down for more posts ▼